# AbbVie Inc. (ABBV) FY2026 Q2 P&L / Income Statement

- Company: AbbVie Inc. (ABBV)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001551152-26-000026
- Page: https://plicit.ai/financials/abbv/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/abbv-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Key Product Portfolio by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Key Product Portfolio by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Net revenues**: 16,990,000,000 US dollars
- **Cost of products sold**: 4,291,000,000 US dollars
- **Gross profit (calculated)**: 12,699,000,000 US dollars
- **Operating expenses (calculated)**: 6,267,000,000 US dollars
- **Operating earnings**: 6,432,000,000 US dollars
- **Other income (expense), net (calculated)**: negative 2,154,000,000 US dollars
- **Earnings before income tax expense**: 4,278,000,000 US dollars
- **Income tax expense**: 662,000,000 US dollars
- **Net earnings**: 3,616,000,000 US dollars
- **Aesthetics - Botox Cosmetic**: 728,000,000 US dollars
- **Aesthetics - Juvederm Collection**: 245,000,000 US dollars
- **Aesthetics - Other Aesthetics**: 309,000,000 US dollars
- **Immunology - Humira**: 756,000,000 US dollars
- **Immunology - Rinvoq**: 2,525,000,000 US dollars
- **Immunology - Skyrizi**: 5,505,000,000 US dollars
- **Neuroscience - Botox Therapeutic**: 1,042,000,000 US dollars
- **Neuroscience - Other Neuroscience**: 117,000,000 US dollars
- **Neuroscience - Qulipta**: 350,000,000 US dollars
- **Neuroscience - Ubrelvy**: 392,000,000 US dollars
- **Neuroscience - Vraylar**: 1,071,000,000 US dollars
- **Neuroscience - Vyalev**: 256,000,000 US dollars
- **Oncology - Elahere**: 211,000,000 US dollars
- **Oncology - Epkinly**: 103,000,000 US dollars
- **Oncology - Imbruvica**: 532,000,000 US dollars
- **Oncology - Venclexta**: 771,000,000 US dollars
- **Other Key Products - Linzess**: 295,000,000 US dollars
- **Other Key Products - Mavyret**: 295,000,000 US dollars
- **Undisclosed (calculated)**: 1,487,000,000 US dollars
- **Selling, general and administrative**: 3,632,000,000 US dollars
- **Research and development**: 2,344,000,000 US dollars
- **Acquired IPR&D and milestones**: 291,000,000 US dollars
- **Other operating income**: 0 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to AbbVie Inc.: $3.61 B; to noncontrolling interests: $3.00 M.